Dexcom said Kevin R. Sayer notified the company of his plans to return from his temporary leave of absence on March 2, 2026, and that upon his return he resumed his duties as Executive Chairman. The filing refers to February 27, 2026 as the date his leave began.

1. 01

   Dexcom said Kevin R. Sayer notified the company of his plans to return from his temporary leave of absence on March 2, 2026, and that upon his return he resumed his duties as Executive Chairman. The filing refers to February 27, 2026 as the date his leave began.

2. 02

   The company said Mark Foletta also resumed his duties as Lead Independent Director when Sayer returned. Sayer had been on temporary leave since September 14, 2025.

3. 03

   Dexcom said it entered into a Letter Agreement with Sayer on February 27, 2026, effective March 2, 2026, providing for an annual base salary of $610,000 and a grant of restricted stock units with a fair value of $2,350,000. The restricted stock units will vest in full on March 8, 2027, subject to Sayer's continued service.

4. 04

   The company said Sayer's equity awards granted before the effective date will continue to vest under their existing terms. It also said he remains eligible for the employee benefit plans offered to other executives, but he is no longer eligible to participate in the Amended and Restated Severance & Change in Control Plan as an executive officer.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.